Participants and eligibility criteria
head injury, idiopathic PD, epilepsy, tremor, stroke, cognitive inability, acute illness, rigidity, PD, bradykinesia, musculoskeletal or neurological disorders, cerebellar or proprioceptive
EPILEPSY, MOVEMENT DISORDERS, STROKE, BRAIN, BRAIN DISEASE, MUSCULOSKELETAL DISORDER, CARDIAC DISEASE, VESTIBULAR PROBLEM
The target population for this study is people with PD who meet the following inclusion criteria for all aims of this trial: 1) diagnosis of idiopathic PD from a movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia and one or more of the following—resting tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions; 2) responsive to levodopa (self-reported); 3) Hoehn & Yahr stages I-III; 4) ages 55–85 years old; 5) ability to follow directions in order to participate in testing procedures and exercise sessions, 6) free of any medical conditions or medication that contraindicates participation in an exercise program and 7) willing and able to participate in 12 sessions of rehabilitation intervention while also refraining from changes to other exercise programs and medications during the study period, within reason.Exclusion criteria are: 1) major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD, significantly affecting gait and balance (i.e., musculoskeletal disorder, vestibular problem, head injury, stroke, cardiac disease, etc.); 2) a medical condition that precludes exercise; 3) cognitive inability to participate in an exercise program, such as Montreal Cognitive Assessment score less than or equal to 19 [